• About us
    • About Lindahl
    • How we work
    • Said about Lindahl
    • Press
    • Find us
    • Privacy
  • Areas
    • Commercial dispute resolution
    • IT/Tech
    • Intellectual property
    • Life Sciences
    • M&A
    • All areas
  • Our people
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Helsingborg
    • Örebro
  • Latest news
    • Cases and transactions
    • News
    • Events
    • Knowledge
    • Portraits
  • Offices
    • Stockholm
    • Göteborg
    • Malmö
    • Uppsala
    • Örebro
    • Helsingborg

Lindahl assists ISR Immune System Regulation Holding in a rights issue of approximately SEK 71.7 million

  • Home
  • Latest news
  • Cases and transactions
  • 2020
  • Lindahl assists ISR Immune System Regulation Holding in a rights issue of approximately SEK 71.7 million

Lindahl is serving as legal advisor when ISR carries out a fully underwritten rights issue of units to shareholders. If the issue is fully subscribed, approximately SEK 71.7 million will be raised for the company on shares issued before costs and expenses relating to the offering. If the issue is fully subscribed and all TO1 warrants are fully exercised within the parameters for the issuance of units, this may raise additional capital of between SEK 23.9 million and SEK 71.7 million for the company, depending on the exercise price. If the issue is fully subscribed and all TO2 warrants are fully exercised within the parameters for the issuance of units, this may raise additional capital of at least SEK 23.9 million for the company, depending on the exercise price. The subscription period for the rights issue runs from 15 May 2020 to 29 May 2020.

ISR Immune System Regulation Holding AB is an innovation-driven research company within the area of immunotherapy. It is listed on the Nasdaq First North Growth Market and is based at the Karolinska Hospital in Stockholm, Sweden. The company is committed to developing immunostimulants, which are drugs that activate the body’s immune system, to treat chronic infections and cancer. The company has two drug development platforms: Immunorhelins, consisting of immune-stimulating Gonadotropin-releasing hormones, where the initial indication is for HIV, and Immunolides, defined as immunostimulating macrolides, where the initial indication is for cancer and HBV, and which are also being evaluated for the treatment of the coronavirus.

The team assigned by the law firm Lindahl to provide ISR with legal support in connection with the rights issue comprised Monica Lagercrantz (responsible partner), Ola Svanberg, Nicklas Bexelius and Lisa Liljekvist. The securities broker Mangold Fondkommission AB served as the financial advisor.

 

Capital markets and public M&A

Lindahl’s competence group for capital markets and public M&A advises Swedish and foreign listed companies and other companies, venture capital companies, banks, investment banks, stockbrokers and other operators in various transactions and matters within the area of capital markets and public M&A.

Visit page

Corporate finance

Lindahl's Corporate Finance team consists of 85 lawyers and is one of the largest in Sweden. Our solid experience and leading market position gives us the opportunity to participate in large projects with complex issues where we help clients to build an understanding of market conditions, challenges, opportunities and risks. We are top ranked in surveys based on client satisfaction and are constantly working to develop our consulting.

Visit page

Contact

  • Monica Lagercrantz

    Stockholm

    monica.lagercrantz@lindahl.se +46 761 269 109
  • Ola Svanberg

    Stockholm

    ola.svanberg@lindahl.se +46 761 269 115
  • Lisa Liljekvist

    Stockholm

Pages
  • Start
  • About us
  • Areas
  • Our people
  • Latest news
  • Privacy
Our offices
  • Stockholm reception.stockholm@lindahl.se +46 8 527 70 800
  • Göteborg reception.goteborg@lindahl.se +46 31 799 10 00
  • Malmö reception.malmo@lindahl.se +46 40 664 66 50
  • Uppsala reception.uppsala@lindahl.se +46 18 16 18 50
  • Örebro reception.orebro@lindahl.se +46 19 20 89 00
  • Helsingborg reception.helsingborg@lindahl.se +46 42 17 53 00
Social media
  • Connect with us on social networks: Instagram, Linkedin, Youtube, Facebook,

Disclaimer

The material and information on this site is intended for general informational purposes only and does not constitute legal advice on any specific matter. Please note that all images on Lindahl's website, www.lindahl.se, are subject to intellectual property protection and downloading, publication, copying and/or other use of the images requires the written consent of the rights holder. You'll find Advokatfirman Lindahl KB's general terms and conditions here.

Some cookies are essential, others help us improve your experience by providing insights into how the site is used. For more information, please visit our Cookie Policy.

Essential Cookies

These cookies are necessary for the functionality of the site and cannot be disabled.

Analytics Cookies>

We use Analytics cookies to collect information that gives us insight into how our website is being used. We anonymize IP addresses in Google Analytics. By clicking on Decline we won't save theese cookies.

Decline
We use cookies to get insights on how our site is used and give our visitors the best possible experience